Beta blockers in HF, reduced EF And Increased HR

Abstract

Care for cardiac patient has been revolutionized throughout the past decades. Despite its initiated safety concerns, beta blockers are now one of the most used and safer drugs for the ailment of heart failure. These have proved not only  effective for heart failure but also for many other conditions such as migraine headaches, breast cancer to reduce the mortality etc.


Keywords: beta blockers, heart failure with reduced ejection fraction, heart rate

Keywords: beta blockers, heart failure with reduced ejection fraction, heart rate

Downloads

Download data is not yet available.

Author Biographies

Arya Babu S A, Doctor of Pharmacy Intern, Indiana Hospital and Heart Institute, Pumpwell, Mangalore, Karnataka, India

Doctor of Pharmacy Intern, Indiana Hospital and Heart Institute, Pumpwell, Mangalore, Karnataka, India

Ajo John, Doctor of Pharmacy Intern, Indiana Hospital and Heart Institute, Pumpwell, Mangalore, Karnataka, India

Doctor of Pharmacy Intern, Indiana Hospital and Heart Institute, Pumpwell, Mangalore, Karnataka, India

References

1. Martinez-Milla J, Raposeiras-Roubin S, Pascual-Figal DA, Ibanez B. Role of beta-blockers in cardiovascular disease in 2019. Revista Española de Cardiología (English Edition). 2019 Oct 1; 72(10):844-52. https://doi.org/10.1016/j.rec.2019.04.014
2. Weber MA. The role of the new β-blockers in treating cardiovascular disease. American journal of hypertension. 2005 Dec 1; 18(S6):169S-76S. https://doi.org/10.1016/j.amjhyper.2005.09.009
3. Steg PG, Ferrari R, Ford I, Greenlaw N, Tardif JC, Tendera M, Abergel H, Fox KM, CLARIFY investigators. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PloS one. 2012 May 3; 7(5):e36284. https://doi.org/10.1371/journal.pone.0036284
4. -Volnes T, Westheim A, Gullestad L, Slind EK, Grundtvig M. β-Blocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure Registry. Biomedicine hub. 2020; 5(1):1-0. https://doi.org/10.1159/000505474
5. Lee PH, Park GM, Han S, Kim YG, Lee JY, Roh JH, Lee JH, Kim YH, Lee SW. Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management. Scientific reports. 2020 Dec 17; 10(1):1-9. https://doi.org/10.1038/s41598-020-79214-0
6. D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer M, Coats AJ, Manzano L, Boehm M, Van Veldhuisen DJ. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. Journal of the American College of Cardiology. 2017 Jun 20; 69(24):2885-96. https://doi.org/10.1016/j.jacc.2017.04.001
7. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. Journal of clinical oncology. 2011 Jul 1; 29(19):2635-44. https://doi.org/10.1200/JCO.2010.33.5422
8. Prabha N, Chhabra N, Arora R. Beta-blockers in dermatology. Indian Journal of Dermatology, Venereology and Leprology. 2017 May 1; 83(3). https://doi.org/10.4103/ijdvl.IJDVL_220_16
9. Kallistratos MS, Poulimenos LE, Manolis AJ. Vasodilator β-blockers: a different class of antihypertensive agents?. Future Cardiology. 2014 Nov; 10(6):669-71. https://doi.org/10.2217/fca.14.51
10. Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. Journal of the American College of Cardiology. 2009 Jan 13; 53(2):184-92. https://doi.org/10.1016/j.jacc.2008.09.031
11. JG, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJ, Manzano L, McMurray JJ, Ruschitzka F, Van Veldhuisen DJ, Von Lueder TG. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European heart journal. 2018 Jan 1; 39(1):26-35. https://doi.org/10.1093/eurheartj/ehx564
12. Karwath A, Bunting KV, Gill SK, Tica O, Pendleton S, Aziz F, Barsky AD, Chernbumroong S, Duan J, Mobley AR, Cardoso VR. Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis. The Lancet. 2021 Oct 16; 398(10309):1427-35. https://doi.org/10.1016/S0140-6736(21)01638-X
13. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta‐blockers for hypertension. Cochrane database of systematic reviews. 2017(1). https://doi.org/10.1002/14651858.CD002003.pub5
14. Fekadu G, Bekele F, Bekele K, Hanbisa S, Belay G, Maqbool M. Drug Use Evaluation of Beta-Blockers in Medical Wards of Nedjo General Hospital, Western Ethiopia. Cardiovascular Therapeutics. 2020 Jun 1; 2020. https://doi.org/10.1155/2020/2509875
15. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta‐blockers for chronic obstructive pulmonary disease. Cochrane database of systematic reviews. 2005(4). https://doi.org/10.1002/14651858.CD003566.pub2
16. Paolillo S, Dell'Aversana S, Esposito I, Poccia A, Filardi PP. The use of β-blockers in patients with heart failure and comorbidities: doubts, certainties and unsolved issues. European Journal of Internal Medicine. 2021 Jun 1; 88:9-14. https://doi.org/10.1016/j.ejim.2021.03.035
17. Chupp GL. Say what, beta-blockers for asthma?. American Journal of Respiratory Cell and Molecular Biology. 2008 Mar; 38(3):249-50. https://doi.org/10.1165/rcmb.2008-0001ED
18. Eldrup-Jorgensen J. Measuring quality and the story of beta blockers. Journal of vascular surgery. 2011 Mar 1; 53(3):845-55. https://doi.org/10.1016/j.jvs.2010.11.091
19. Ostrowska M, Kubica J. Carvedilol-is it still the primus inter pares among b-blockers?. Medical Research Journal. 2018; 3(3):165-74. https://doi.org/10.5603/MRJ.2018.0028
20. Thalheimer U, Bosch J, Burroughs AK. An apology for beta blockers. Journal of hepatology. 2014 Aug 1; 61(2):450-1. https://doi.org/10.1016/j.jhep.2014.03.040
21. Chrysant SG, Chrysant GS. Antihypertensive and cardioprotective effects of three generations of beta-adrenergic blockers: an historical perspective. Hospital Practice. 2022 Feb 13(just-accepted). https://doi.org/10.1080/21548331.2022.2040920
22. Chourdakis E, Koniari I, Velissaris D, Tsigkas G, Kounis NG, Osman N. Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives. Journal of Geriatric Cardiology: JGC. 2021 May 5; 18(5):362.
23. Niriayo YL, Asgedom SW, Demoz GT, Gidey K. Treatment optimization of beta-blockers in chronic heart failure therapy. Scientific Reports. 2020 Sep 28; 10(1):1-8. https://doi.org/10.1038/s41598-020-72836-4
24. Deliver E, Mayor Jr F, D'Ocon P. Beta-blockers: historical perspective and mechanisms of action. Revista Española de Cardiología (English Edition). 2019 Oct 1; 72(10):853-62. https://doi.org/10.1016/j.rec.2019.04.006
Statistics
26 Views | 6 Downloads
How to Cite
1.
S A AB, John A. Beta blockers in HF, reduced EF And Increased HR. JDDT [Internet]. 15Nov.2022 [cited 9Dec.2022];12(6):224-6. Available from: https://jddtonline.info/index.php/jddt/article/view/5730